临床心身疾病杂志
臨床心身疾病雜誌
림상심신질병잡지
JOURNAL OF CLINICAL PSYCHOSOMATIC DISEASES
2014年
4期
34-36
,共3页
精神分裂症%喹硫平%氯氮平%阳性与阴性症状量表%副反应量表
精神分裂癥%喹硫平%氯氮平%暘性與陰性癥狀量錶%副反應量錶
정신분렬증%규류평%록담평%양성여음성증상량표%부반응량표
Schizophrenia%quetiapine%clozapine%PANSS%TESS
目的:探讨喹硫平与氯氮平治疗女性精神分裂症的临床疗效和安全性。方法将86例女性精神分裂症患者随机分为两组,分别口服喹硫平与氯氮平治疗,观察8周。采用阳性与阴性症状量表评定临床疗效、副反应量表评定不良反应。结果治疗8周末喹硫平组总有效率为88.4%,氯氮平组为86.0%,两组比较差异无显著性(χ2=0.10,P>0.05);喹硫平组不良反应较轻微,其中嗜睡、月经紊乱、泌乳、体质量增加、心电图及脑电图异常等不良反应发生率显著低于氯氮平组(P<0.05)。结论喹硫平与氯氮平治疗女性精神分裂症疗效显著且相当,但喹硫平对女性内分泌的影响甚微,不增加体质量,更适用于女性精神分裂症患者。
目的:探討喹硫平與氯氮平治療女性精神分裂癥的臨床療效和安全性。方法將86例女性精神分裂癥患者隨機分為兩組,分彆口服喹硫平與氯氮平治療,觀察8週。採用暘性與陰性癥狀量錶評定臨床療效、副反應量錶評定不良反應。結果治療8週末喹硫平組總有效率為88.4%,氯氮平組為86.0%,兩組比較差異無顯著性(χ2=0.10,P>0.05);喹硫平組不良反應較輕微,其中嗜睡、月經紊亂、泌乳、體質量增加、心電圖及腦電圖異常等不良反應髮生率顯著低于氯氮平組(P<0.05)。結論喹硫平與氯氮平治療女性精神分裂癥療效顯著且相噹,但喹硫平對女性內分泌的影響甚微,不增加體質量,更適用于女性精神分裂癥患者。
목적:탐토규류평여록담평치료녀성정신분렬증적림상료효화안전성。방법장86례녀성정신분렬증환자수궤분위량조,분별구복규류평여록담평치료,관찰8주。채용양성여음성증상량표평정림상료효、부반응량표평정불량반응。결과치료8주말규류평조총유효솔위88.4%,록담평조위86.0%,량조비교차이무현저성(χ2=0.10,P>0.05);규류평조불량반응교경미,기중기수、월경문란、비유、체질량증가、심전도급뇌전도이상등불량반응발생솔현저저우록담평조(P<0.05)。결론규류평여록담평치료녀성정신분렬증료효현저차상당,단규류평대녀성내분비적영향심미,불증가체질량,경괄용우녀성정신분렬증환자。
Objective To investigate the clinical efficacy and safety of quetiapine and clozapine in the treat-ment of female schizophrenia .Methods Eighty-six female schizophrenics were randomly divided into two groups of 43 ones each ,they took orally quetiapine and clozapine respectively for 8 weeks .The clinical ef-ficacies were assessed with the Positive and Negative Syndrome Scale (PANSS) and adverse reactions with the Treatment Emergent Symptom Scale (TESS) .Results At the end of the 8th week ,total effective rate was respectively 88 .4% in quetiapine and 86 .0% in clozapine group ,which showed no significant differ-ence (P>0 .05) .Adverse reactions of quetiapine group were mild and the incidences of such adverse reac-tions were significantly lower compared with clozapne as lethargy ,menstrual disorder ,lactation ,weight gain ,abnormal ECG and EEG (P<0 .05) .Conclusion Quetiapine has an evident effect equivalent to cloz-apine in the treatment of female schizophrenia ,but the former does smaller influence on female endocrine , doesn’t raise body mass ,and is more suitable for female schizophrenics .